Raptor Pharmaceutical (RPTP -22%) stumbles hard out of the gate, despite announcing that its...

|About: Raptor Pharmaceutical Corp. (RPTP)|By:, SA News Editor

Raptor Pharmaceutical (RPTP -22%) stumbles hard out of the gate, despite announcing that its Phase 3 clinical trial of DR Cysteamine has met the primary endpoint.